These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 16267003

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3).
    Okamoto S, Takamizawa S, Bishop W, Wen J, Kimura K, Sandler A.
    J Surg Res; 1999 Jun 01; 84(1):77-81. PubMed ID: 10334893
    [Abstract] [Full Text] [Related]

  • 24. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Huerta-Yepez S, Vega M, Garban H, Bonavida B.
    Clin Immunol; 2006 Sep 01; 120(3):297-309. PubMed ID: 16784892
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A, Tada Y, Kawamura K, Takiguchi Y, Tatsumi K, Kuriyama T, Takenouchi T, O-Wang J, Tagawa M.
    Cancer Gene Ther; 2007 Mar 01; 14(3):262-7. PubMed ID: 17053813
    [Abstract] [Full Text] [Related]

  • 29. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC.
    Oncol Rep; 2003 Mar 01; 10(1):57-63. PubMed ID: 12469145
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
    Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K.
    Int J Oncol; 2001 Jan 01; 18(1):33-9. PubMed ID: 11115536
    [Abstract] [Full Text] [Related]

  • 33. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F, von der Maase H, Marcussen N, Hamilton-Dutoit S, Madsen HH, Jensen JJ, Hokland M.
    Clin Cancer Res; 2004 Dec 01; 10(23):7911-6. PubMed ID: 15585624
    [Abstract] [Full Text] [Related]

  • 34. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
    Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I.
    Cancer Res; 2001 Jan 15; 61(2):577-81. PubMed ID: 11212252
    [Abstract] [Full Text] [Related]

  • 35. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
    Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, Shi Y, Tan W, Zhou Y, Zhao D, Zhang X, Guo Y, Lin D.
    Carcinogenesis; 2007 May 15; 28(5):1067-73. PubMed ID: 17183065
    [Abstract] [Full Text] [Related]

  • 36. [The "Fas counterattack": a mechanism for immune evasion in human hilar cholangiocarcinomas].
    Li Z, Zhang L, Zou S.
    Zhonghua Yi Xue Za Zhi; 2002 May 10; 82(9):606-9. PubMed ID: 12133481
    [Abstract] [Full Text] [Related]

  • 37. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
    Lee SH, Bar-Haim E, Goldberger O, Reich-Zeliger S, Vadai E, Tzehoval E, Eisenbach L.
    Immunol Lett; 2004 Feb 15; 91(2-3):119-26. PubMed ID: 15019279
    [Abstract] [Full Text] [Related]

  • 38. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS, Koh S, Huang E, Saff RR, Marshak-Rothstein A, Mukai S, Ksander BR.
    Invest Ophthalmol Vis Sci; 2005 Jul 15; 46(7):2495-502. PubMed ID: 15980241
    [Abstract] [Full Text] [Related]

  • 39. Significant inhibition of human CD8(+) cytotoxic T lymphocyte-mediated xenocytotoxicity by overexpression of the human decoy Fas antigen.
    Kawamoto K, Tanemura M, Nishida T, Fukuzawa M, Ito T, Matsuda H.
    Transplantation; 2006 Mar 15; 81(5):789-96. PubMed ID: 16534484
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.